Literature DB >> 30927247

Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia.

Yuka Kurokawa1, Kiyomi Koike1, Yusuke Kaida1, Sakuya Ito1, Hirotane Chiba1, Kengo Urae1, Tomofumi Moriyama1, Nao Nakamura1, Tetsurou Imai2, Ryo Shibata1, Takuma Hazama1, Daisuke Wakasugi1, Seiya Okuda1, Kei Fukami3.   

Abstract

A 65-year-old male patient with nephrotic syndrome was admitted to our hospital due to worsening systemic edema and purpura on the limbs. He had an impaired renal function, low serum complement level, and elevated rheumatoid factor level. He was positive for cryoglobulin (monoclonal IgM-κ and polyclonal mixed-type IgG), and the results of his kidney biopsy showed a tissue profile of membranoproliferative glomerulonephritis (MPGN). Due to the fact that the secondary cause was unclear, he was diagnosed with MPGN due to essential mixed cryoglobulinemia. On hospital day 20, he was initiated on 50 mg/day prednisolone (PSL). On hospital day 43, oral mizoribine (MZR) at a dose of 150 mg/day was prescribed. On hospital day 49, cryofiltration was performed because the disease was steroid resistant. The treatment promptly decreased urine protein levels. Serum albumin and serum complement levels increased, and complete remission was achieved approximately three months after the initiation of treatment. The PSL and MZR doses were gradually reduced to 2 mg/day and 100 mg/day, respectively, without any reemergence of the symptoms of cryoglobulinemia or relapse of the nephrotic syndrome for three years. Here, we report this case with essential mixed cryoglobulinemia in whom we could achieve complete remission of the disease by adding cryofiltration to the oral corticosteroid and immunosuppressant therapy with mizoribine and could maintain for a long time.

Entities:  

Keywords:  Cryofiltration; Cryoglobulin; Membranoproliferative glomerulonephritis; Mizoribine

Mesh:

Substances:

Year:  2019        PMID: 30927247      PMCID: PMC6620224          DOI: 10.1007/s13730-019-00394-4

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  23 in total

Review 1.  Cryoglobulinemic vasculitis.

Authors:  Clodoveo Ferri; Maria Teresa Mascia
Journal:  Curr Opin Rheumatol       Date:  2006-01       Impact factor: 5.006

2.  Inhibitory mechanism of mizoribine on the antibody production of mouse B cells stimulated with lipopolysaccharide.

Authors:  H Kamada; H Itoh; H Shibata; T Koshio; A Hayashi; K Nakagami
Journal:  Jpn J Pharmacol       Date:  1997-08

Review 3.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

4.  Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hitoshi Yokoyama; Hitoshi Sugiyama; Hiroshi Sato; Takashi Taguchi; Michio Nagata; Seiichi Matsuo; Hirofumi Makino; Tsuyoshi Watanabe; Takao Saito; Yutaka Kiyohara; Shinichi Nishi; Hiroyuki Iida; Kunio Morozumi; Atsushi Fukatsu; Tamaki Sasaki; Kazuhiko Tsuruya; Yukimasa Kohda; Makoto Higuchi; Hideyasu Kiyomoto; Shin Goto; Motoshi Hattori; Hiroshi Hataya; Shoji Kagami; Norishige Yoshikawa; Yuichiro Fukasawa; Yoshihiko Ueda; Hiroshi Kitamura; Akira Shimizu; Kazumasa Oka; Naoki Nakagawa; Takafumi Ito; Shunya Uchida; Kengo Furuichi; Izaya Nakaya; Satoshi Umemura; Keiju Hiromura; Mitsuhiro Yoshimura; Nobuhito Hirawa; Takashi Shigematsu; Masafumi Fukagawa; Makoto Hiramatsu; Yoshio Terada; Osamu Uemura; Tetsuya Kawata; Akira Matsunaga; Aki Kuroki; Yasukiyo Mori; Koji Mitsuiki; Haruyoshi Yoshida
Journal:  Clin Exp Nephrol       Date:  2012-10-11       Impact factor: 2.801

5.  Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein.

Authors:  S Takahashi; H Wakui; J A Gustafsson; J Zilliacus; H Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-07-21       Impact factor: 3.575

6.  [Successful treatment of acute renal failure in a patient with essential mixed cryoglobulinemia using prednisolone and cryofiltration].

Authors:  Y Wada; T Saeki; S Miyamura; Y Osawa; M Ueno; S Nishi; M Arakawa
Journal:  Nihon Jinzo Gakkai Shi       Date:  1999-01

7.  Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

Authors:  Naoki Nakagawa; Naoyuki Hasebe; Motoshi Hattori; Michio Nagata; Hitoshi Yokoyama; Hiroshi Sato; Hitoshi Sugiyama; Akira Shimizu; Yoshitaka Isaka; Shoichi Maruyama; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-12-06       Impact factor: 2.801

8.  Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010.

Authors:  Hitoshi Sugiyama; Hitoshi Yokoyama; Hiroshi Sato; Takao Saito; Yukimasa Kohda; Shinichi Nishi; Kazuhiko Tsuruya; Hideyasu Kiyomoto; Hiroyuki Iida; Tamaki Sasaki; Makoto Higuchi; Motoshi Hattori; Kazumasa Oka; Shoji Kagami; Tetsuya Kawamura; Tetsuro Takeda; Hiroshi Hataya; Yuichiro Fukasawa; Atsushi Fukatsu; Kunio Morozumi; Norishige Yoshikawa; Akira Shimizu; Hiroshi Kitamura; Yukio Yuzawa; Seiichi Matsuo; Yutaka Kiyohara; Kensuke Joh; Michio Nagata; Takashi Taguchi; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2013-02-06       Impact factor: 2.801

9.  Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.

Authors:  Clodoveo Ferri; Marco Sebastiani; Dilia Giuggioli; Massimiliano Cazzato; Giovanni Longombardo; Alessandro Antonelli; Rodolfo Puccini; Claudio Michelassi; Anna Linda Zignego
Journal:  Semin Arthritis Rheum       Date:  2004-06       Impact factor: 5.532

10.  Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.

Authors:  A Tarantino; M Campise; G Banfi; R Confalonieri; A Bucci; A Montoli; G Colasanti; I Damilano; G D'Amico; L Minetti
Journal:  Kidney Int       Date:  1995-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.